# Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit

> **NCT02211859** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 70 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** BI 2536

## Key facts

- **NCT ID:** NCT02211859
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2007-12
- **Final completion:** —
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2024-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02211859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02211859, "Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02211859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*